[
  {
    "ts": "2026-02-11T13:00:00+00:00",
    "headline": "Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award",
    "summary": "SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent’s trade‑in and buyback program.",
    "url": "https://finance.yahoo.com/news/agilent-presents-boehringer-ingelheim-inaugural-130000649.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "64f553e5-48d6-32ad-84ed-5b20b937bf8d",
      "content": {
        "id": "64f553e5-48d6-32ad-84ed-5b20b937bf8d",
        "contentType": "STORY",
        "title": "Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award",
        "description": "",
        "summary": "SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent’s trade‑in and buyback program.",
        "pubDate": "2026-02-11T13:00:00Z",
        "displayTime": "2026-02-11T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/d6629eaa3a45bef75f04d27274ce2a70",
          "originalWidth": 1000,
          "originalHeight": 404,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4DJvGA0Q5YLGdCd1fFFiYw--~B/aD00MDQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d6629eaa3a45bef75f04d27274ce2a70.cf.webp",
              "width": 1000,
              "height": 404,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XY8nM9vN9lWFULk_ZJqvWg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d6629eaa3a45bef75f04d27274ce2a70.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/agilent-presents-boehringer-ingelheim-inaugural-130000649.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/agilent-presents-boehringer-ingelheim-inaugural-130000649.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "A"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T11:45:00+00:00",
    "headline": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)",
    "summary": "SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.",
    "url": "https://finance.yahoo.com/news/agilent-receives-fda-approval-pd-114500053.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "f1e04c13-ee6a-337d-bb05-8f200b17e962",
      "content": {
        "id": "f1e04c13-ee6a-337d-bb05-8f200b17e962",
        "contentType": "STORY",
        "title": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)",
        "description": "",
        "summary": "SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.",
        "pubDate": "2026-02-11T11:45:00Z",
        "displayTime": "2026-02-11T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad",
          "originalWidth": 1000,
          "originalHeight": 404,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PQWewlSpOjq3LBzkeZ9umg--~B/aD00MDQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad.cf.webp",
              "width": 1000,
              "height": 404,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W0iu6UMRdyYDW2qH3YUL1w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/agilent-receives-fda-approval-pd-114500053.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/agilent-receives-fda-approval-pd-114500053.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "A"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]